{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:16:36Z","timestamp":1792196196391,"version":"4.4.0"},"reference-count":113,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T00:00:00Z","timestamp":1650153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PIE13\/00046"],"award-info":[{"award-number":["PIE13\/00046"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe","award":["2013\/0331"],"award-info":[{"award-number":["2013\/0331"]}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe","award":["2019-052-1"],"award-info":[{"award-number":["2019-052-1"]}]},{"name":"Red Tem\u00e1tica de Investigaci\u00f3n Cooperativa en C\u00e1ncer","award":["RD12\/0036\/014"],"award-info":[{"award-number":["RD12\/0036\/014"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Antineoplastic uptake by blast cells in acute myeloid leukemia (AML) could be influenced by influx and efflux transporters, especially solute carriers (SLCs) and ATP-binding cassette family (ABC) pumps. Genetic variability in SLC and ABC could produce interindividual differences in clinical outcomes. A systematic review was performed to evaluate the influence of SLC and ABC polymorphisms and their combinations on efficacy and safety in AML cohorts. Anthracycline intake was especially influenced by SLCO1B1 polymorphisms, associated with lower hepatic uptake, showing higher survival rates and toxicity in AML studies. The variant alleles of ABCB1 were related to anthracycline intracellular accumulation, increasing complete remission, survival and toxicity. Similar findings have been suggested with ABCC1 and ABCG2 polymorphisms. Polymorphisms of SLC29A1, responsible for cytarabine uptake, demonstrated significant associations with survival and response in Asian populations. Promising results were observed with SLC and ABC combinations regarding anthracycline toxicities. Knowledge of the role of transporter pharmacogenetics could explain the differences observed in drug disposition in the blast. Further studies including novel targeted therapies should be performed to determine the influence of genetic variability to individualize chemotherapy schemes.<\/jats:p>","DOI":"10.3390\/pharmaceutics14040878","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T02:39:31Z","timestamp":1650335971000},"page":"878","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-5341","authenticated-orcid":false,"given":"Juan Eduardo","family":"Meg\u00edas-Vericat","sequence":"first","affiliation":[{"name":"Servicio de Farmacia, \u00c1rea del Medicamento, Hospital Universitario y Polit\u00e9cnico La Fe, Avda. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-4091","authenticated-orcid":false,"given":"David","family":"Mart\u00ednez-Cuadr\u00f3n","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda y Hemoterapia, Hospital Universitario y Polit\u00e9cnico La Fe, Avda. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8804-3878","authenticated-orcid":false,"given":"Antonio","family":"Solana-Altabella","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, \u00c1rea del Medicamento, Hospital Universitario y Polit\u00e9cnico La Fe, Avda. Fernando Abril Martorell 106, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, Avda. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-6198","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Poveda","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, \u00c1rea del Medicamento, Hospital Universitario y Polit\u00e9cnico La Fe, Avda. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda y Hemoterapia, Hospital Universitario y Polit\u00e9cnico La Fe, Avda. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.25484","article-title":"Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia","volume":"94","author":"Medeiros","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2217\/pgs-2016-0055","article-title":"Pharmacogenomics and the treatment of acute myeloid leukemia","volume":"17","author":"Montesinos","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1389200218666171101124931","article-title":"Pharmaco-genetics of metabolic genes of anthracyclines in acute myeloid leukemia","volume":"19","author":"Herrero","year":"2018","journal-title":"Curr. Drug Metab."},{"key":"ref_5","first-page":"335","article-title":"Profiling of drug-metabolizing enzymes\/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin","volume":"13","author":"Iacobucci","year":"2012","journal-title":"Pharm. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2217\/14622416.8.6.567","article-title":"Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients","volume":"8","author":"Lal","year":"2007","journal-title":"Pharmacogenomics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bjc.6605587","article-title":"Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide","volume":"102","author":"Bray","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1124\/mol.116.105544","article-title":"Contribution of Organic Anion-Transporting Polypeptides 1A\/1B to Doxorubicin Uptake and Clearance","volume":"91","author":"Lee","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic Anion Transporting Polypeptide 1B1: A Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FPC.0b013e328333b99c","article-title":"PharmGKB very important pharmacogene: SLCO1B1","volume":"20","author":"Oshiro","year":"2010","journal-title":"Pharm. Genom."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ijc.28797","article-title":"In vivo disposition of doxorubicin is affected by mouse Oatp1a\/1b and human OATP1A\/1B transporters","volume":"135","author":"Durmus","year":"2014","journal-title":"Int. J. Cancer."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/cpt.315","article-title":"Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia","volume":"99","author":"Drenberg","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/10428194.2020.1839650","article-title":"Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemo-therapy in acute myeloid leukemia","volume":"62","author":"Herrero","year":"2021","journal-title":"Leuk. Lymphoma."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yee, S.W., and Giacomini, K.M. (2021). Emerging Roles of the Human Solute Carrier 22 Family. Drug metabolism and disposition: The biological fate of chemicals. Drug Metab. Dispos., 50.","DOI":"10.1124\/dmd.121.000702"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/jhg.2013.38","article-title":"Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia","volume":"58","author":"Yee","year":"2013","journal-title":"J. Hum. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10495-015-1137-x","article-title":"Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells","volume":"20","author":"Wu","year":"2015","journal-title":"Apoptosis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.leukres.2007.10.011","article-title":"Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups","volume":"32","author":"Asher","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1359-6349(09)71933-0","article-title":"9242 Pharmacogenetic factors in metabolism, transport and toxicity of cytarabine treatment in patients with AML","volume":"7","author":"Seeringer","year":"2009","journal-title":"Eur. J. Cancer Suppl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12967-017-1339-9","article-title":"Polymorphisms at microRNA binding sites of Ara-C and an-thracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients","volume":"15","author":"Cao","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00424-003-1107-y","article-title":"The concentrative nucleoside transporter family, SLC28","volume":"447","author":"Gray","year":"2004","journal-title":"Pfl\u00fcgers Archiv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Canadian Pharmacogenomics Network for Drug Safety Consortium. Pharmacogenomic prediction of anthracycline-induced cardio-toxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/pbc.24505","article-title":"Validation of variants inSLC28A3andUGT1A6as genetic markers predictive of anthracycline-induced cardiotoxicity in children","volume":"60","author":"Visscher","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ng.3374","article-title":"Canadian Phar-macogenomics Network for Drug Safety Consortium. A coding variant in RARG confers susceptibility to anthracy-cline-induced cardiotoxicity in childhood cancer","volume":"47","author":"Aminkeng","year":"2015","journal-title":"Nat Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s12885-018-4629-6","article-title":"Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma","volume":"18","author":"Egyed","year":"2018","journal-title":"BMC Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10549-015-3437-9","article-title":"Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients","volume":"152","author":"Vulsteke","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/pgs.14.179","article-title":"Association of NADPH oxidase poly-morphisms with anthracycline-induced cardiotoxicity in the RICOVER60 trial of patients with aggressive CD20(+) B-cell lymphoma","volume":"16","author":"Reichwagen","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zeller, T., Wild, P., Szymczak, S., Rotival, M., Schillert, A., Castagne, R., Maouche, S., Germain, M., Lackner, K., and Rossmann, H. (2010). Genetics and beyond--the tran-scriptome of human monocytes and disease susceptibility. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010693"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1126\/science.1174148","article-title":"Common Regulatory Variation Impacts Gene Expression in a Cell Type\u2013Dependent Manner","volume":"325","author":"Dimas","year":"2009","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1172\/JCI112823","article-title":"Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells","volume":"79","author":"White","year":"1987","journal-title":"J. Clin. Investig."},{"key":"ref_32","first-page":"459","article-title":"Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro","volume":"29","author":"Kessel","year":"1969","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"45270","DOI":"10.1074\/jbc.M107169200","article-title":"Topology of a Human Equilibrative, Nitrobenzylthioinosine (NBMPR)-sensitive Nucleoside Transporter (hENT1) Implicated in the Cellular Uptake of Adenosine and Anti-cancer Drugs","volume":"276","author":"Sundaram","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood.V90.1.346.346_346_353","article-title":"Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein","volume":"90","author":"Gati","year":"1997","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10555-007-9044-4","article-title":"The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs","volume":"26","author":"Zhang","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1084\/jem.20050177","article-title":"HIF-1\u2013dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia","volume":"202","author":"Eltzschig","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.bbrc.2012.02.035","article-title":"PPARalpha and PPARgamma regulate the nucleoside transporter hENT1","volume":"419","author":"Montero","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1365-2141.2002.03538.x","article-title":"In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia","volume":"117","author":"Galmarini","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1080\/15257770.2020.1746803","article-title":"Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia","volume":"39","author":"Jaramillo","year":"2020","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00008571-200305000-00010","article-title":"Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1","volume":"13","author":"Osato","year":"2003","journal-title":"Pharmacogenetics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.fpc.0000189804.41962.15","article-title":"Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1","volume":"16","author":"Myers","year":"2006","journal-title":"Pharm. Genom."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2217\/pgs.10.200","article-title":"Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells","volume":"12","author":"Parmar","year":"2011","journal-title":"Pharmacogenomics"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00280-016-3103-x","article-title":"SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia","volume":"78","author":"Kim","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejca.2012.07.022","article-title":"Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients","volume":"49","author":"Kim","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13046-014-0090-9","article-title":"SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: An in vitro study","volume":"33","author":"Wan","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12185-015-1766-4","article-title":"Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy","volume":"101","author":"Amaki","year":"2015","journal-title":"Int. J. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"International Transporter Consortium, Giacomini, K.M., Huang, S.M., Tweedie, D.J., Benet, L.Z., Brouwer, K.L., Chu, X., Dahlin, A., Evers, R., and Fischer, V. (2010). Membrane transporters in drug development. Nat. Rev. Drug Discov., 9, 215\u2013236.","DOI":"10.1038\/nrd3028"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1349-7006.2008.00744.x","article-title":"Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients","volume":"99","author":"Lal","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1158\/1078-0432.CCR-08-0442","article-title":"Expression of ABCC-Type Nucleotide Exporters in Blasts of Adult Acute Myeloid Leukemia: Relation to Long-term Survival","volume":"15","author":"Guo","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/0008-5472.CAN-08-1420","article-title":"Human Multidrug Resistance Protein 7 (ABCC10) Is a Resistance Factor for Nucleoside Analogues and Epothilone B","volume":"69","author":"Xu","year":"2009","journal-title":"Cancer Res."},{"key":"ref_51","first-page":"4955","article-title":"MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients","volume":"62","author":"Illmer","year":"2002","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.20427","article-title":"Identification of polymorphisms on theMDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients","volume":"80","author":"Kaya","year":"2005","journal-title":"Am. J. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1200\/jco.2005.23.16_suppl.6550","article-title":"Multidrug resistance-1 gene polymorphism associated with the treatment outcomes in de novo acute myeloid leukemia","volume":"23","author":"Kim","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clpt.2006.07.005","article-title":"ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients","volume":"80","author":"Vandenheuveleibrink","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.leukres.2007.12.013","article-title":"C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia","volume":"32","author":"Hur","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_56","first-page":"201","article-title":"Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia","volume":"1","author":"Hampras","year":"2010","journal-title":"Int. J. Mol. Epidemiol. Genet."},{"key":"ref_57","first-page":"111","article-title":"Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype","volume":"12","author":"Falk","year":"2010","journal-title":"Pharm. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00432-012-1170-x","article-title":"ABCB1 genetic variation and P-glycoprotein expression\/activity in a cohort of Brazilian acute myeloid leukemia patients","volume":"138","author":"Scheiner","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/bjh.13097","article-title":"Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype","volume":"167","author":"Fyrberg","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.clinthera.2014.06.016","article-title":"Association of ABCB1 Polymorphisms with the Efficacy of Ondansetron in Chemotherapy-induced Nausea and Vomiting","volume":"36","author":"He","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00228-014-1795-6","article-title":"Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia","volume":"71","author":"He","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1080\/10428194.2016.1231405","article-title":"Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia","volume":"58","author":"Montesinos","year":"2017","journal-title":"Leuk. Lymphoma."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41408-019-0211-y","article-title":"ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: A report from Children\u2019s Oncology Group AAML0531 Trial","volume":"9","author":"Rafiee","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"E225","DOI":"10.1002\/ajh.25854","article-title":"Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with de-citabine plus gemtuzumab ozogamicin","volume":"95","author":"Short","year":"2020","journal-title":"Am. J Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.V97.11.3605","article-title":"MDR1 gene\u2013related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia","volume":"97","author":"Wiemer","year":"2001","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1182\/blood.V116.21.1714.1714","article-title":"Prognostic Impact of DNA Repair and MDR-1 Gene Polymorphisms In De Novo Acute Myeloid Leukemia with t(8;21) or Inv(16)","volume":"116","author":"Kim","year":"2010","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1182\/blood.V110.11.4271.4271","article-title":"Prognostic Significance of ABCB1 (MDR1) Gene Polymorphisms in De Novo Acute Myeloid Leukemia with t(8;21) or inv(16)","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1182\/blood-2005-08-3272","article-title":"Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia","volume":"107","author":"Monzo","year":"2006","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00280-016-3166-8","article-title":"Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia","volume":"78","author":"Varatharajan","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2141.2000.01793.x","article-title":"P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells","volume":"108","author":"Borg","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1158\/1078-0432.CCR-07-1484","article-title":"Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials","volume":"13","author":"Seedhouse","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.clpt.2005.11.013","article-title":"MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype","volume":"79","author":"Lamba","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_73","first-page":"109","article-title":"Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies","volume":"15","author":"Rojas","year":"2015","journal-title":"Pharm. J."},{"key":"ref_74","first-page":"1","article-title":"Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: A systematic review and meta-analysis","volume":"16","author":"Rojas","year":"2016","journal-title":"Pharm. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2217\/pgs.15.162","article-title":"Evidence for association of SNPs in ABCB1 and CBR3 but not RAC2, NCF4 SLC28A3 or TOP2B with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines","volume":"17","author":"Hertz","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/leu.2008.398","article-title":"Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21","volume":"23","author":"Rossi","year":"2009","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3389\/fgene.2013.00231","article-title":"A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase poly-morphisms as a potential risk factor","volume":"4","author":"Lubieniecka","year":"2013","journal-title":"Front. Genet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1124\/mol.118.114827","article-title":"Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters","volume":"96","author":"Sissung","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1124\/mol.52.3.344","article-title":"Pharmacological Characterization of the Murine and Human Orthologs of Multidrug-Resistance Protein in Transfected Human Embryonic Kidney Cells","volume":"52","author":"Stride","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00008571-200206000-00008","article-title":"A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance","volume":"12","author":"Conrad","year":"2002","journal-title":"Pharmacogenetics"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/CBI20110264","article-title":"ABCC1polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia","volume":"36","author":"Semsei","year":"2012","journal-title":"Cell Biol. Int."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4238\/vol7-4gmr482","article-title":"MRP1 polymorphisms (T2684C, C2007T, C2012T, and C2665T) are not associated with multidrug resistance in leukemic patients","volume":"7","author":"Mahjoubi","year":"2008","journal-title":"Genet. Mol. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00277-020-04163-7","article-title":"Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia","volume":"99","author":"Kunadt","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_84","first-page":"929","article-title":"Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells","volume":"55","author":"Cui","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.12516","article-title":"Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation","volume":"163","author":"Armenian","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/cncr.26472","article-title":"Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: A pilot study","volume":"118","author":"Windsor","year":"2012","journal-title":"Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2217\/pgs-2016-0150","article-title":"ATP-binding casette transporter expression in acute myeloid leukemia: Association with in vitro cytotoxicity and prognostic markers","volume":"18","author":"Varatharajan","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"100729","DOI":"10.1016\/j.currproblcancer.2021.100729","article-title":"ABCC3 and GSTM5 gene polymorphisms affect overall survival in Polish acute myeloid leukaemia patients","volume":"45","author":"Butrym","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6062","DOI":"10.1158\/1078-0432.CCR-09-0048","article-title":"Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters","volume":"15","author":"Hu","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/jnci\/djr107","article-title":"Activity of the Multikinase Inhibitor Sorafenib in Combination with Cytarabine in Acute Myeloid Leukemia","volume":"103","author":"Hu","year":"2011","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.apsb.2019.01.007","article-title":"Development of precision medicine approaches based on interindividual variability of BCRP\/ABCG2","volume":"9","author":"Chen","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood.V96.1.365","article-title":"Expression of breast cancer resistance protein in blast cells from patients with acute leukemia","volume":"96","author":"Ross","year":"2000","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1158\/1078-0432.CCR-04-0795","article-title":"Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias","volume":"10","author":"Benderra","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7764","DOI":"10.1158\/1078-0432.CCR-04-1895","article-title":"MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia","volume":"11","author":"Benderra","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/cncr.25753","article-title":"Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse","volume":"117","author":"Tiribelli","year":"2010","journal-title":"Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.ejca.2011.03.032","article-title":"Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia","volume":"47","author":"Wang","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.3324\/haematol.2012.075895","article-title":"Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy","volume":"98","author":"Tiribelli","year":"2013","journal-title":"Haematologica"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/187231207779814328","article-title":"ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan","volume":"1","author":"Rhodes","year":"2007","journal-title":"Drug Metab. Lett."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00280-009-1138-y","article-title":"Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics\/pharmacodynamics in Japanese cancer patients","volume":"66","author":"Sai","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2217\/pgs.10.81","article-title":"Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction","volume":"11","author":"Peters","year":"2010","journal-title":"Pharmacogenomics"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1021\/mp400202d","article-title":"An Integrated in Vitro Model for Simultaneous Assessment of Drug Uptake, Metabolism, and Efflux","volume":"10","author":"Neve","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF03256426","article-title":"Assessing Gene-Gene Interactions in Pharmacogenomics","volume":"16","author":"Lane","year":"2012","journal-title":"Mol. Diagn. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"121770","DOI":"10.1016\/j.jchromb.2019.121770","article-title":"Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS\/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients","volume":"1126\u20131127","author":"Donnette","year":"2019","journal-title":"J. Chromatogr. B"},{"key":"ref_105","first-page":"244","article-title":"Association of genetic poly-morphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia","volume":"33","author":"Yamakawa","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"ref_106","first-page":"770","article-title":"SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia","volume":"52","author":"Zhang","year":"2014","journal-title":"Zhonghua Er Ke Za Zhi\u2014Chin. J. Pediatr."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/17425255.2014.952630","article-title":"Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance","volume":"10","author":"Bruhn","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17425255.2021.1876661","article-title":"ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: What is our current understanding?","volume":"17","author":"Bruckmueller","year":"2021","journal-title":"Expert Opin. Drug. Metab. Toxicol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.2217\/pgs.09.130","article-title":"Pharmacogenomics in acute myeloid leukemia","volume":"10","author":"Roumier","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2217\/pgs.12.102","article-title":"The clinically relevant pharmacogenomic changes in acute myelogenous leukemia","volume":"13","author":"Emadi","year":"2012","journal-title":"Pharmacogenomics"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"103281","DOI":"10.1016\/j.critrevonc.2021.103281","article-title":"Update on drug transporter proteins in acute myeloid leukemia: Pathological implication and clinical setting","volume":"160","author":"Vasconcelos","year":"2021","journal-title":"Crit. Rev. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Pinto-Merino, \u00c1., Labrador, J., Zubiaur, P., Alcaraz, R., Herrero, M.J., Montesinos, P., Abad-Santos, F., and Saiz-Rodr\u00edguez, M. (2022). Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030559"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00277-020-04186-0","article-title":"Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia","volume":"99","author":"Montesinos","year":"2020","journal-title":"Ann. Hematol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/4\/878\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:55:40Z","timestamp":1760136940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/4\/878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,17]]},"references-count":113,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["pharmaceutics14040878"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14040878","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,17]]}}}